• A40926: Anti-Neisseria Glycopeptide Discovery

  2026-08-15

  The 1987 reference study identified A40926 as a lipid-containing glycopeptide with activity that extended beyond the usual Gram-positive spectrum to include Neisseria gonorrhoeae. Its affinity-resin discovery strategy, factor characterization, comparative susceptibility testing, bactericidal analysis, and mouse pharmacology established a useful framework for subsequent glycopeptide and anti-infective research.

• Clodronate Liposomes for Macrophage Depletion

  2026-08-15

  Clodronate Liposomes provide a practical, time-controlled approach to in vivo macrophage depletion, helping researchers test whether macrophages causally shape tumor immunity rather than merely correlate with disease. This guide connects phagocytosis-mediated delivery with tissue-specific workflows, orthogonal validation, and colorectal cancer immunotherapy research.

• Phytol Workflows for RXR Signaling Assays

  2026-08-14

  Build more informative RXR experiments with Phytol by combining concentration-response design, solvent controls, and metabolism-aware follow-up assays. This workflow also distinguishes mixed-isomer Phytol from trans-Phytol and uses orthogonal GABAergic and PPARα readouts to expose pathway-specific effects.

• Sulfaphenazole Restores Perfusion After Skin Injury

  2026-08-14

  The reference study shows that Sulfaphenazole can reduce pressure- and thermal-injury severity in ischemia–reperfusion models by rapidly restoring tissue perfusion. Its findings connect CYP2C inhibition, oxidative stress reduction, improved wound repair, and macrophage antibacterial activity in a preclinical framework.

• WAY-100635 for Causal 5-HT1A Assay Design

  2026-08-13

  WAY-100635 enables precise serotonin receptor antagonist research by testing whether 5-HT1A signaling contributes to sensory, affective, and cognitive effects in inflammatory pain models. This article presents a causal assay framework that connects receptor pharmacology with the latest cannabidiol findings without overstating the evidence.

• PD98059 MEK Inhibitor: Applied Workflows

  2026-08-13

  PD98059 enables branch-specific MAPK/ERK experiments spanning leukemia differentiation, cell-cycle arrest, apoptosis, and ischemic injury models. This practical guide connects dose design, pathway validation, phenotype measurement, and troubleshooting so researchers can distinguish effective MEK inhibition from nonspecific toxicity.

• EZ Cap EGFP mRNA 5-moUTP Workflow Guide

  2026-08-12

  Learn how to use EZ Cap EGFP mRNA 5-moUTP as a reproducible EGFP reporter for delivery screening, translation efficiency assays, and cell-based expression studies. Practical handling guidance and a delivery-vector framework help distinguish RNA quality problems from uptake, endosomal escape, and intracellular-release limitations.

• Urolithin A: Assay Strategy for Mitochondrial Stress

  2026-08-12

  Urolithin A research benefits from separating mitophagy, respiration, inflammation, and metabolic-state effects rather than relying on a single endpoint. This guide connects mitochondrial assays with hepatic stellate cell metabolism and provides practical parameters for interpretable studies.

• BAPTA Calcium Chelator in Cell Signaling

  2026-08-11

  BAPTA is a high-affinity calcium chelator used to reduce free Ca2+ and interrogate calcium-dependent signaling. Product specifications and a 2026 intestinal-cell study support its use in apoptosis research, while also defining important limits for interpretation.

• N6-Methyl-dATP: An Assay-Design Guide

  2026-08-10

  N6-Methyl-dATP offers a controlled way to test how adenine methylation changes DNA polymerase behavior. This guide connects nucleotide-level assay design with the LMO2/LDB1 AML literature while separating established evidence from forward-looking applications.

• Lumiracoxib: A Time-Resolved COX-2 Assay Strategy

  2026-08-09

  Lumiracoxib enables selective COX-2 pathway modulation without treating inflammation as a single static endpoint. This guide translates venom-induced muscle injury findings into time-resolved assay design, endpoint selection, and practical compound-handling decisions.

• Bufalin–CRISPR/Cas9 Nanomedicine for CRC

  2026-08-08

  The reference study presents a calcium lactate nanoparticle system that co-delivers bufalin and CRISPR/Cas9 ribonucleoproteins targeting CD47 in colorectal cancer. By combining pyroptosis, apoptosis, macrophage M1 repolarization, and enhanced tumor-cell phagocytosis, the platform links direct tumor damage with immune remodeling.

• Gemcitabine HCl in MRI-Guided Cancer Models

  2026-08-07

  Combine Gemcitabine HCl with multianimal MRI to connect DNA synthesis inhibition in cultured cells with longitudinal tumor measurements in pancreatic cancer models. This workflow improves treatment-group enrollment, dose tracking, and interpretation of tumor growth suppression while exposing common assay and imaging failure points.

• Gemcitabine HCl: Mechanism and Preclinical Evidence in Pancr

  2026-08-07

  Gemcitabine HCl, a deoxycytidine analog, is a potent inhibitor of DNA synthesis with validated cytotoxicity against pancreatic cancer cell lines. Its robust in vitro and in vivo efficacy, coupled with defined solubility and storage parameters, underpins its widespread adoption in translational oncology workflows.

• IR-820 (New Indocyanine Green): Reliable Near-Infrared Imagi

  2026-08-06

  This article addresses practical challenges with cell viability and tumor imaging assays, demonstrating how IR-820 (New Indocyanine Green, SKU C8228) delivers reproducible, quantitative near-infrared fluorescence for advanced biomedical workflows. Scenario-driven Q&A guides researchers on optimizing protocols and selecting reliable suppliers.

453 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page